- Home
- RPRX vs INCY Comparison
RPRX vs INCY Comparison
Compare RPRX & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- INCY
- Stock Information
- Founded
- RPRX 1996
- INCY 1991
- Country
- RPRX United States
- INCY United States
- Employees
- RPRX N/A
- INCY N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- RPRX Health Care
- INCY Health Care
- Exchange
- RPRX Nasdaq
- INCY Nasdaq
- Market Cap
- RPRX 13.9B
- INCY 13.4B
- IPO Year
- RPRX 2020
- INCY 1993
- Fundamental
- Price
- RPRX $33.58
- INCY $70.07
- Analyst Decision
- RPRX Strong Buy
- INCY Hold
- Analyst Count
- RPRX 3
- INCY 20
- Target Price
- RPRX $47.33
- INCY $71.94
- AVG Volume (30 Days)
- RPRX 5.5M
- INCY 1.9M
- Earning Date
- RPRX 05-08-2025
- INCY 07-29-2025
- Dividend Yield
- RPRX 2.62%
- INCY N/A
- EPS Growth
- RPRX 37.60
- INCY N/A
- EPS
- RPRX 2.45
- INCY 0.10
- Revenue
- RPRX $2,263,845,000.00
- INCY $4,413,226,000.00
- Revenue This Year
- RPRX $29.35
- INCY $13.29
- Revenue Next Year
- RPRX $7.58
- INCY $10.47
- P/E Ratio
- RPRX $13.70
- INCY $728.16
- Revenue Growth
- RPRX 1.13
- INCY 17.13
- 52 Week Low
- RPRX $24.05
- INCY $53.56
- 52 Week High
- RPRX $34.32
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- RPRX 56.69
- INCY 73.97
- Support Level
- RPRX $33.37
- INCY $63.51
- Resistance Level
- RPRX $33.97
- INCY $70.97
- Average True Range (ATR)
- RPRX 0.53
- INCY 1.76
- MACD
- RPRX 0.05
- INCY 0.46
- Stochastic Oscillator
- RPRX 76.06
- INCY 87.94
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.